Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- FOLD
- Price
- 6.48
- Stock movement down
- -0.03 (-0.46%)
- Company name
- Amicus Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.94B
- Ent value
- 2.31B
- Price/Sales
- 3.92
- Price/Book
- 10.83
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 17.77
- PEG
- -
- EPS growth
- -22.84%
- 1 year return
- -42.50%
- 3 year return
- -11.22%
- 5 year return
- -8.49%
- 10 year return
- -5.48%
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
FOLD does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 125.59 |
| EV to EBITDA | 149.86 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.92 |
| Price to Book | 10.83 |
| EV to Sales | 4.68 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 298.81M |
| EPS (TTM) | -0.34 |
| FCF per share (TTM) | -0.10 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 493.67M |
| Gross profit (TTM) | 437.72M |
| Operating income (TTM) | 11.26M |
| Net income (TTM) | -104.69M |
| EPS (TTM) | -0.34 |
| EPS (1y forward) | 0.36 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 88.67% |
| Operating margin (TTM) | 2.28% |
| Profit margin (TTM) | -21.21% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 233.65M |
| Net receivables | 98.07M |
| Total current assets | 498.47M |
| Goodwill | 197.80M |
| Intangible assets | 18.03M |
| Property, plant and equipment | 82.91M |
| Total assets | 786.56M |
| Accounts payable | 13.48M |
| Short/Current long term debt | 444.66M |
| Total current liabilities | 158.14M |
| Total liabilities | 607.73M |
| Shareholder's equity | 178.82M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -26.52M |
| Capital expenditures (TTM) | 5.00M |
| Free cash flow (TTM) | -31.51M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -58.54% |
| Return on Assets | -13.31% |
| Return on Invested Capital | -17.88% |
| Cash Return on Invested Capital | -5.38% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 6.50 |
| Daily high | 6.78 |
| Daily low | 6.33 |
| Daily Volume | 3.81M |
| All-time high | 24.89 |
| 1y analyst estimate | 17.33 |
| Beta | 0.67 |
| EPS (TTM) | -0.34 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| FOLD | S&P500 | |
| Current price drop from All-time high | -73.97% | -12.89% |
| Highest price drop | -89.91% | -56.47% |
| Date of highest drop | 16 Apr 2014 | 9 Mar 2009 |
| Avg drop from high | -53.34% | -11.07% |
| Avg time to new high | 150 days | 12 days |
| Max time to new high | 1970 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.94B
Marketcap category
Small-cap
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Employees
500
Website
Investor relations
-
SEC filings
CEO
John Francis Crowley
Country
USA
City
Cranbury
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page